title: Acneiform rash during lung cancer therapy with erlotinib (Tarceva(®)).
abstract: Tyrosine kinase inhibitors are currently applied in the treatment of non-small cell lung cancer with overexpressed epidermal growth factor receptor (EGFR). Acneiform rash is the earliest and most characteristic side effect of EGFR inhibition. The incidence may be as high as 50-100% of cases. We report a case of a 47-year-old patient who developed acneiform rash after 1.5 weeks of treatment with erlotinib.
authors.affiliation: Department of Dermatology, Sexually Transmited Diseases and Clinical Immunology, Municipal Hospital, Olsztyn, Poland. Head: Prof. Waldemar Placek MD, PhD.
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Owczarczyk-Saczonek
authors.forename: Henryk
authors.initials: H
authors.lastname: Witmanowski
authors.forename: Waldemar
authors.initials: W
authors.lastname: Placek
keywords: acneiform-rash; erlotynib; tyrosine kinase inhibitors